The global sepsis diagnostics market was valued at USD 548.2 million in 2019 and is expected to grow at a CAGR of 8.5% during the forecast period. The key factors responsible for the market growth are the unattended sepsis cases in the low and middle-income countries coupled with the construction of government hospitals in the remote rural areas, innovations in the sepsis diagnostic with the advent of new biomarkers, and the introduction of technologically advanced sepsis diagnostic automated systems in the market.
Know more about this report: request for sample pages
Sepsis is a severe medical condition triggered by a strong immune response with the onset of any infection. The high prevalence across the globe posing a huge threat to humans. As per the statistics published by the WHO, in 2018, over 30 million individuals, worldwide suffered from sepsis, with an alarming annual mortality rate of 5 percent. It also stated that each year around 3 million infants and 1.2 million children suffer from this condition. This demand-side factor is crucial for market growth.
For instance, in October 2018, the U.S.-based Duke University Hospital introduced “Sepsis Watch” an AI system to identify the onset of early stages of sepsis for patients in the emergency and intensive care unit. The system identifies health indicators such as medical histories, lab tests, and vital signs. The system was able to pull the patient’s data every 5 minutes to evaluate medical conditions. It alerts the hospital’s nurse to make informed decisions based on a patient’s condition using standard protocols by the Surviving Sepsis Program introduced in the market.
The major triggering factors for market growth for sepsis include hospital-acquired infections (HAIs), particularly in old age, infants, and people suffering from some co-morbidities. As per the estimates of the Center for Disease and Control (CDC), every year almost 1.7 million people suffer from HAIs and around 99,000 patients die due to the lack of medical care in the U.S. alone. Hence, the economic burden on the people is huge, with the majority of the revenue in the market churned from the sepsis diagnostics and treatment procedure.
The current tests being time-consuming, with an average test time of up to 72 hours to decipher final results and key observations. Thereby, demand for the point of care and rapid sepsis test kits in the market for early diagnosis could save millions of lives. In line with this, in February 2019, the researchers studying at the University of Strathclyde developed a cost-effective sepsis diagnostic system. It uses the micro-electrode inserted into the blood vessel and analyzes blood metrics in two and a half minutes. The key players in the market-place are collaborating with the university to make the developed system commercially viable, and the companies can have a first-mover advantage.
In line with this, there is an increased industry activity, for instance, in September 2020, Barcelona based, Loop Diagnostics, developed a point of care diagnosis platform. According to the company’s claim, the product would replace traditional methods of blood culture analysis. The basic idea was to identify bacterial infections via blood-based markers and would be able to provide test results in two hours with a 99 percent accuracy rate. The cost of the diagnosis with this system would be USD 70, as per the company claim. Early diagnosis, also opines lesser hospital expense on sepsis treatment. As per the independent survey in the market, 2018, the cost of sepsis treatment upon admission is almost USD 22,000, in comparison to USD 70,000 per patient for hospital-acquired sepsis.
The market is primarily segmented on the basis of product, technology, pathogen, testing type, and region.
By Testing Type
Know more about this report: request for sample pages
Based upon the product, the global diagnostics market is categorized into instruments, blood culture media, assay kits & reagents, and software. In 2019, blood culture media is estimated to account for the largest share and is projected to maintain its dominance over the study period. This is due to the fact that blood culture is still the most cost-effective and gold standard method preferred by most physicians.
The kits & reagents market segment is anticipated to showcase the highest growth rate over the forecast period. This is attributed to the continuously rising demand for reagents & kits for diagnostic, particularly in the developed economies. As per the study published by the American Medical Association (AMA), by February 2019, sepsis was a major death cause in the hospitals and impacted the lives of around 1.7 million individuals in the U.S. Thus, with the need for rapid diagnosis in the hospitals and clinics, the sale of reagent and kits is bound to increase in the market.
On the basis of diagnostic technology, the microbiology segment held a major market share in the global market, in 2019. The segment’s high share is due to the fact that microbiology involves the identification and detection of microbes in the blood culture media, with the help of well-trained microbiologists. The molecular diagnostic segment is projected to exhibit the highest CAGR over the study period. The technique is considered as a gold standard after blood culture in pathogen identification.
North America market accounts for one of the largest revenue holders in the global market and is likely to maintain its dominance over the study period. The favorable reimbursement scenario for the diagnostic tests, well developed medical and clinical infrastructure, intellectual ability of the key players operating in the country.
Moreover, the country with high disposable income and spending patterns, bound to attract the vested interest of the key diagnostics companies in the market. According to the data reported by the health economist of the U.S.-based CDC National Healthcare Safety Network, the annual burden of HAIs in the U.S. alone stood between USD 28 to USD 45 billion each year.
Asia Pacific market is anticipated to exhibit a lucrative growth rate over the projected period for diagnostics. The rising cases of sepsis both in hospital and non-hospital settings with increasing medical literacy and awareness, rising insurance penetration rate, and the rise in per capita medical expense from the rural areas in the countries across the region. As per estimates of the PLOS, in 2019, India had a very high incidence rate for clinical sepsis, and it also impacted the lives of sufferers.
Some of the major players operating the market include bioMérieux, Axis-Shield Diagnostics, Becton Dickinson, Danaher Corporation, Abbott Laboratories, Luminex, Thermo Fisher Scientific, EKF Diagnostics, Immunexpress, Bruker, Roche Diagnostics, T2 Biosystems, Response Biomedical, and CytoSorbents.